Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/01455613211000170 http://scihub22266oqcxt.onion/10.1177/01455613211000170 33729897!?!33729897 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33729897&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Ear+Nose+Throat+J 2023 ; 102 (5): 323-328 Nephropedia Template TP {{tp|p=33729897|t=2023. Comparative Study of Chemosensory Dysfunction in COVID-19 in 2 Geographically Distinct Regions |pdf=|usr=}}{{33729897}} gab.com Text Comparative Study of Chemosensory Dysfunction in COVID-19 in 2 Geographically Distinct Regions JO: Ear Nose Throat J http://www.kidney.de/pget.php?&tw=1&pmid=33729897 #FOAvip OBJECTIVE: To directly compare the prevalence of chemosensory dysfunction (smell and taste) in geographically distinct regions with the same questionnaires. METHODS: A cross-sectional study was performed to evaluate the self-reported symptoms among adults (older than 18 years) who underwent COVID-19 testing at an ambulatory assessment center in Canada and at a hospital in Israel between March 16, 2020, and August 19, 2020. The primary outcome was the prevalence of self-reported chemosensory dysfunction (anosmia/hypomsia and dysgeusia/ageusia). Subgroup analysis was performed to evaluate the prevalence of chemosensory deficits among the outpatients. RESULTS: We identified a total of 350 COVID-19-positive patients (138 Canadians and 212 Israelis). The overall prevalence of chemosensory dysfunction was 47.1%. There was a higher proportion of chemosensory deficits among Canadians compared to Israelis (66.7% vs 34.4%, P < .01). A subgroup analysis for outpatients (never hospitalized) still identified a higher prevalence of chemosensory dysfunction among Canadians compared to Israelis (68.2% vs 36.1%, P < 0.01). A majority of patients recovered their sense of smell after 4 weeks of symptom onset. CONCLUSION: Although the prevalence of chemosensory deficit in COVID-19 was found to be similar to previously published reports, the prevalence can vary significantly across different geographical regions. Therefore, it is important to obtain regionally specific data so that the symptom of anosmia/dysgeusia can be used as a guide for screening for the clinical diagnosis of COVID-19. Twit Text FOAVip Comparative Study of Chemosensory Dysfunction in COVID-19 in 2 Geographically Distinct Regions ????Ear Nose Throat J http://www.kidney.de/pget.php?&tw=1&pmid=33729897 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33729897 #FOAvip English Wikipedia <ref>{{Cite pmid|33729897}}</ref> Comparative Study of Chemosensory Dysfunction in COVID-19 in 2 Geographically Distinct Regions #MMPMID33729897 Lee DJ; Daliyot D; Wang R; Lockwood J; Das P; Zimlichman E; Lee JM Ear Nose Throat J 2023[May]; 102 (5): 323-328 PMID33729897show ga OBJECTIVE: To directly compare the prevalence of chemosensory dysfunction (smell and taste) in geographically distinct regions with the same questionnaires. METHODS: A cross-sectional study was performed to evaluate the self-reported symptoms among adults (older than 18 years) who underwent COVID-19 testing at an ambulatory assessment center in Canada and at a hospital in Israel between March 16, 2020, and August 19, 2020. The primary outcome was the prevalence of self-reported chemosensory dysfunction (anosmia/hypomsia and dysgeusia/ageusia). Subgroup analysis was performed to evaluate the prevalence of chemosensory deficits among the outpatients. RESULTS: We identified a total of 350 COVID-19-positive patients (138 Canadians and 212 Israelis). The overall prevalence of chemosensory dysfunction was 47.1%. There was a higher proportion of chemosensory deficits among Canadians compared to Israelis (66.7% vs 34.4%, P < .01). A subgroup analysis for outpatients (never hospitalized) still identified a higher prevalence of chemosensory dysfunction among Canadians compared to Israelis (68.2% vs 36.1%, P < 0.01). A majority of patients recovered their sense of smell after 4 weeks of symptom onset. CONCLUSION: Although the prevalence of chemosensory deficit in COVID-19 was found to be similar to previously published reports, the prevalence can vary significantly across different geographical regions. Therefore, it is important to obtain regionally specific data so that the symptom of anosmia/dysgeusia can be used as a guide for screening for the clinical diagnosis of COVID-19. |*COVID-19[MESH] |*Olfaction Disorders/diagnosis[MESH] |Adult[MESH] |Anosmia[MESH] |COVID-19 Testing[MESH] |Canada[MESH] |Cross-Sectional Studies[MESH] |Dysgeusia/diagnosis[MESH] |Humans[MESH]Comparative Study of Chemosensory Dysfunction in COVID-19 in 2 Geograp(epmc).pdf DeepDyve Pubget Overpricing